A Case of Oxaliplatin-Related Ocular Toxicity.

Park, Han Seok; Kim, Yang Jae; Song, Su Jeong; Bae, Jeong Hun

doi:2014.55.1.143

J Korean Ophthalmol Soc > Volume 55(1); 2014 > Article

Case Report

Journal of the Korean Ophthalmological Society 2014;55(1):143-148.
DOI: https://doi.org/10.3341/jkos.2014.55.1.143 Published online January 15, 2014.

A Case of Oxaliplatin-Related Ocular Toxicity.

Han Seok Park, Yang Jae Kim, Su Jeong Song, Jeong Hun Bae

Department of Ophthalmology, Kangbuk Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. jhbae94@hotmail.com

Oxaliplatin에 의한 안독성의 1예

박한석⋅김양재⋅송수정⋅배정훈

Department of Ophthalmology, Kangbuk Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Abstract

PURPOSE
To report a case of oxaliplatin (Eloxatin(R))-related ocular toxicity in a patient with advanced stomach cancer. CASE SUMMARY: A 43-year-old female with advanced stomach cancer experienced visual symptoms during the treatment with oxaliplatin on a XELOX schedule (a combination of oxaliplatin and capecitabine). After 1 cycle of chemotherapy, she complained of blurred vision and visual field defects in both eyes. Visual field tests showed a bilateral concentric field defect and the electroretinogram revealed a marked reduction of responses in both eyes. On the second cycle of chemotherapy, oxaliplatin was discontinued due to suspicious ocular toxicity. Her visual symptoms improved and visual field test showed normal results 1 month after oxaliplatin discontinuation. However, 3 months after oxaliplatin discontinuation, electroretinogram remained abnormal despite the progressive improvement. CONCLUSIONS: Platinum-based antineoplastic agents such as oxaliplatin should be administered with caution because oxaliplatin can cause damage to the retinal photoreceptors and the optic nerve. Early detection of ocular toxicity and discontinuation of oxaliplatin therapy could prevent severe and irreversible visual loss.

Key Words: Electroretinogram;Ocular toxicity;Oxaliplatin;XELOX